Propanc Biopharma Book Value Per Share vs. Beta
| PPCB Stock | USD 0.0002 0.0001 33.33% |
For Propanc Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Propanc Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Propanc Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Propanc Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Propanc Biopharma over time as well as its relative position and ranking within its peers.
Propanc |
Propanc Biopharma Beta vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Propanc Biopharma's current stock value. Our valuation model uses many indicators to compare Propanc Biopharma value to that of its competitors to determine the firm's financial worth. Propanc Biopharma is considered to be number one stock in book value per share category among its peers. It also is considered to be number one stock in beta category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Propanc Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Propanc Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Propanc Beta vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Propanc Biopharma |
| = | (0) X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Propanc Biopharma |
| = | 1.42 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Propanc Beta Comparison
Propanc Biopharma is currently under evaluation in beta category among its peers.
Beta Analysis
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Propanc Biopharma will likely underperform.
Propanc Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Propanc Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Propanc Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Propanc Biopharma's change in net profit over the period of time. It can combine multiple indicators of Propanc Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Propanc Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Propanc Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Propanc Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Propanc Biopharma's important profitability drivers and their relationship over time.
Use Propanc Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Propanc Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Propanc Biopharma will appreciate offsetting losses from the drop in the long position's value.Propanc Biopharma Pair Trading
Propanc Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Propanc Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Propanc Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Propanc Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Propanc Biopharma to buy it.
The correlation of Propanc Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Propanc Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Propanc Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Propanc Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Propanc Biopharma position
In addition to having Propanc Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Propanc Pink Sheet
To fully project Propanc Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Propanc Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Propanc Biopharma's income statement, its balance sheet, and the statement of cash flows.